The EUROMACS Registry of Patients Who Receive Mechanical Circulatory Support: Role and Perspectives



Fig. 58.1
Kaplan Myer analysis: overall survival of all MCS devices



The overall actuarial survival of 2850 patients receiving a primary implantation with a MCS device at 6 months, 1, 2, 3, and 4 years is respectively 73.7%, 66.5%, 56.2%, 48.4%, and 38.4%. Patients at risk are 488 (2 years), 178 (3 years), and 45 (4 years).

◘ Table 58.1 provides a breakdown of the INTERMACS levels of the MCS patients in the EUROMACS registry.


Table 58.1
INTERMACS levels of 2172 VAD implantations
















































INTERMACS level
n

%

Critical cardiogenic shock
383
13.4

Progressive decline
879
30.8

Stable but inotrope dependent
697
24.5

Resting symptoms
509
17.8

Exertion intolerant
88
3.1

Exertion limited
37
1.3

Advanced NYHA class III
33
1.2

Unspecified
224
7.9

Total (%)
2850
100.0


NYHA New York Heart Association

Only gold members can continue reading. Log In or Register to continue

Related posts:

  1. Low INTERMACS Profiles: One-Stage Durable LVAD Implantation for INTERMACS Level 1: Indications and Contraindications
  2. Mechanical Circulatory Support in Pediatric Population: Clinical Considerations, Indications, Strategies, and Postoperative Management
  3. Temporary RVAD
  4. Percutaneous Devices: Options

Stay updated, free articles. Join our Telegram channel
Tags:
Nov 3, 2017 | Posted by in CARDIOLOGY | Comments Off on The EUROMACS Registry of Patients Who Receive Mechanical Circulatory Support: Role and Perspectives

Full access? Get Clinical Tree
Get Clinical Tree app for offline access